BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
|
|
BOM : 524663     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Jul 06,2022 |
Price(EOD): ₹ 26.75
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 115.56 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION | -4.5% | -4.5% | -60.3% |
SUN PHARMACEUTICAL INDUSTRIES | -0.3% | -3% | 21% |
DIVIS LABORATORIES | 0.7% | 3.1% | -16.5% |
DR REDDYS LABORATORIES | 0.6% | 1.9% | -19.6% |
CIPLA | -0.8% | -3.9% | -4.9% |
GLAND PHARMA | -4.6% | -11.1% | -23% |
PIRAMAL ENTERPRISES | 2% | -5.5% | -29.9% |
CADILA HEALTHCARE | 1.5% | -0.9% | -43.6% |
TORRENT PHARMACEUTICALS | 1.8% | 4.2% | -0.7% |
FUNDAMENTAL ANALYSIS OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
-
P/E Calculated based on EPS of -4.19
[ Mar2021 - Standalone Results ] 3.39
P/B Calculated based on Book Value of 7.88
[ Mar2021 - Standalone Results ] 1.42
P/S Calculated based on Revenues of 81.546 Cr
[ TTM - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA 99% -9% |
SHARE PRICE MOMENTUM OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION vs SENSEX
DEBT OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
0.8 0.15 1.05 0.67 |
- - - - |
[Last Annual Data : Mar2021]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-29.44% 129.05% 90.33% 96.46% |
-31.26% 122.54% 92.1% 91.44% |
QtrlyTrend |
4 | |
Latest Qtr: Dec2021 | ||
Quarterly Result Analysis → |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION related INDICES
You may also like the below Video Courses
FAQ about BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
Is BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION good for long term investment?
As on Jul 06,2022, the Fundamentals of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION look Poor and hence it may not be good for long term investment ! See Financial Performance of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION UnderValued or OverValued?
As on Jul 06,2022, BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION ?
As on Jul 06,2022, the Intrinsic Value of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION is Rs. 21.38 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -11.36
Fair Value [Median EV / Sales Model] : Rs. 13.46
Fair Value [Median Price / Sales Model] : Rs. 29.30
Median Fair Value of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION : Rs. 21.38
Is BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION trading at a Premium or Discount?
As on Jul 06,2022, BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION is trading at a Premium of 25% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
